Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Protalix BioTherapeutics (PLX) Return on Equity (2016 - 2025)

Historic Return on Equity for Protalix BioTherapeutics (PLX) over the last 16 years, with Q3 2025 value amounting to 0.11%.

  • Protalix BioTherapeutics' Return on Equity rose 4200.0% to 0.11% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.11%, marking a year-over-year increase of 4200.0%. This contributed to the annual value of 0.08% for FY2024, which is 3800.0% down from last year.
  • Latest data reveals that Protalix BioTherapeutics reported Return on Equity of 0.11% as of Q3 2025, which was up 4200.0% from 0.13% recorded in Q2 2025.
  • In the past 5 years, Protalix BioTherapeutics' Return on Equity ranged from a high of 9.66% in Q4 2021 and a low of 10.46% during Q3 2021
  • Moreover, its 5-year median value for Return on Equity was 0.14% (2023), whereas its average is 0.6%.
  • Per our database at Business Quant, Protalix BioTherapeutics' Return on Equity crashed by -106700bps in 2021 and then skyrocketed by 121300bps in 2022.
  • Over the past 5 years, Protalix BioTherapeutics' Return on Equity (Quarter) stood at 9.66% in 2021, then tumbled by -87bps to 1.3% in 2022, then tumbled by -89bps to 0.14% in 2023, then crashed by -46bps to 0.08% in 2024, then surged by 37bps to 0.11% in 2025.
  • Its last three reported values are 0.11% in Q3 2025, 0.13% for Q2 2025, and 0.09% during Q1 2025.